Elegolix reduces endometriosis-related work loss, saves costs

In: PharmacoEconomics & Outcomes News · 2019 · vol. 832(1) , pp. 11 · doi:10.1007/s40274-019-6037-9 · W4229829021
article OA: closed CC0
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite+body, 2026-07-19 ⓘ

This study estimated elagolix's impact on endometriosis-associated work loss and costs based on two phase III clinical trials.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-10 · read from full text ⓘ

This analysis utilized data from two phase III clinical trials to estimate the economic impact of elagolix on work loss associated with endometriosis. The researchers calculated that by reducing pain symptoms, the medication significantly decreased absenteeism and presenteeism among affected patients compared to placebo. These reductions in productivity loss translated into substantial cost savings for employers and healthcare systems over the study period. This paper is centrally about endometriosis — specifically evaluating the pharmacoeconomic benefits of elagolix treatment for managing endometriosis-associated pain.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 573 characters · extracted from oa-doi-fallback · click to expand
Reference Pokrzywinski RM, et al. Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials. Fertility and Sterility : 18 Jun 2019. Available from: URL: http://doi.org/10.1016/j.fertnstert.2019.04.031 Rights and permissions About this article Cite this article Elegolix reduces endometriosis-related work loss, saves costs. PharmacoEcon Outcomes News 832, 11 (2019). https://doi.org/10.1007/s40274-019-6037-9 Published: Version of record: Issue date: DOI: https://doi.org/10.1007/s40274-019-6037-9

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-09-26T06:30:31.687879+00:00
License: CC0 · commercial use OK